Genelux GNLX
NASDAQ GNLX
$2.06 -0.01 (-0.72%)
As of: Oct 22, 2026 · 10:43 AM EDT

Genelux (GNLX) Current Deferred Revenue (2022)

Updated

Genelux (GNLX) recorded Current Deferred Revenue of $170,000 in Q4 2022.

Analysis

Genelux (GNLX) Current Deferred Revenue (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,166.12 Bn 1,134.70 Bn 19.71 Bn
2 Johnson & Johnson 634.67 Bn 553.20 Bn 17.26 Bn
3 AbbVie 503.03 Bn 476.14 Bn 12.70 Bn
4 Merck 377.66 Bn 332.04 Bn 12.21 Bn
5 Novartis Ag 303.82 Bn 267.81 Bn 11.24 Bn
6 Astrazeneca 266.80 Bn 240.49 Bn 12.86 Bn
7 Amgen 240.87 Bn 196.27 Bn 7.24 Bn
8 Gilead Sciences 193.45 Bn 167.65 Bn 6.22 Bn
9 Pfizer 172.20 Bn 118.84 Bn 10.94 Bn
10 Genelux 90.94 Mn 29.22 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 170,000.00
API Access

Genelux Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=GNLX&period=max&api_key=YOUR_API_KEY